Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 6/2020

01-06-2020 | Expression of Concern

Expression of Concern: shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells

Authors: Hongjian Yang, Yue Lu, Yabing Zheng, Xingfei Yu, Xianghou Xia, Xiangming He, Weiliang Feng, Lei Xing, Zhiqiang Ling

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2020

Login to get access

Excerpt

The Editors-in-Chief would like to alert readers that there are some concerns related to this article [1]. Concern has been raised that there are textual and formatting similarities to this retracted article [2]. There are also concerns about the construction of experimental reagents in the methods, as well as in the phrases selected for reporting cell cycle influences. While we recognize that the overlap could result from recycling of language with similar experimental methodologies, particularly by authors whose first language is not English, we have not received any response from the authors regarding the above concerns. None of the authors have responded to correspondence about this Expression of Concern. Readers are advised to interpret the details of this article with caution. …
Metadata
Title
Expression of Concern: shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells
Authors
Hongjian Yang
Yue Lu
Yabing Zheng
Xingfei Yu
Xianghou Xia
Xiangming He
Weiliang Feng
Lei Xing
Zhiqiang Ling
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2020
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-020-04044-w

Other articles of this Issue 6/2020

Cancer Chemotherapy and Pharmacology 6/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine